Lagos, Nigeria — The National Agency for Food and Drug Administration and Control (NAFDAC) has announced the recall of a specific batch of Deekins Amoxicillin 500mg capsules following reports of severe adverse reactions.
The affected batch, identified as lot number 4C639001, was manufactured by Eco-med Pharma Ltd and marketed by DevineKings Pharmaceutical Ltd. The recall was made public in a statement released on Wednesday via NAFDAC’s official X (formerly Twitter) account.
Reason for Recall
The decision to recall the product follows reports of three severe adverse drug reactions in patients treated with capsules from this specific batch. According to the manufacturer, Eco-med Pharma Ltd, these incidents were reported by a hospital that had administered the medication to its patients.
NAFDAC confirmed the seriousness of the situation, emphasizing the need to safeguard public health.
“Reports of serious adverse drug reactions were received from a hospital regarding this batch of Deekins Amoxicillin 500mg capsules,” the statement read.
About Amoxicillin
Amoxicillin, a widely used penicillin-based antibiotic, is prescribed for treating a variety of bacterial infections, including:
- Tonsillitis
- Bronchitis
- Sinusitis
- Pneumonia
- Bacterial infections of the ear, nose, throat, skin, and urinary tract
While generally considered safe when administered correctly, adverse reactions can occur, highlighting the importance of strict quality control measures.
Advisory to Healthcare Providers and Consumers
NAFDAC has urged healthcare professionals and consumers to immediately discontinue the use of the affected batch. The agency has also requested that any suspected cases of substandard or falsified medicines be reported.
“Healthcare professionals and consumers are advised to report any suspicion of substandard and falsified medicines to the nearest NAFDAC office, call 0800-162-3322, or email sf.alert@nafdac.gov.ng,” the statement added.
Next Steps and Monitoring
NAFDAC assured the public that it is actively monitoring the situation and working closely with Eco-med Pharma Ltd and DevineKings Pharmaceutical Ltd to ensure that the defective product is removed from circulation. The agency also reiterated its commitment to protecting public health through rigorous surveillance and prompt action.
Consumers and healthcare providers are advised to remain vigilant and report any adverse reactions to safeguard public health.
